Prematurity and HIV present a complex challenge, with biologic underpinnings that are often confounded by a myriad of other factors that coexist in this high-risk population. Furthermore, many of the current management options designed to reduce mother-to-infant transmission, including antiretroviral therapy and cesarean birth, may each have an independent effect on prematurity. These issues notwithstanding, knowledge gained from randomized controlled trials and epidemiologic studies has made a significant impact on the approach to this challenging public health problem worldwide. This article discusses the significance, contribution, and management of perinatal transmission of HIV in prematurity.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados